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Replication causes desquamation of epithelial cells, which induces changes in regional lymphatic tissue, including hypertrophy and active, proliferative germinal centers and can result in lymphadenopathy and intussusception, particularly in children. 15, 16 The innate and adaptive immune responses are critical for the control of adenovirus replication. 17, 18 CD4+ and CD8+ T lymphocytes play a particularly important role in the control and clearance of replicating adenovirus in humans with deficits associated with progressive dissemination in immunosuppressed patients. 4, [19] [20] [21] Group-and type-specific neutralizing and non-neutralizing antibodies play a significant role, too, in limiting infection. 22 
Prevention
Vaccination and careful attention to infection control practices are the only existing preventative strategies. 11 To date, the vaccine is only available to members of the military in the USA who are 17-50 years old. 11 Contact and droplet precautions are recommended to prevent healthcare-associated and institutional outbreaks of adenovirus infections, including epidemic keratoconjunctivitis. 23 Likewise, careful attention to hand hygiene and standard sterilization of medical equipment that comes in contact with patients with proven or suspected adenovirus infection is essential. 24 
Diagnostic Microbiology
Diagnosis of adenovirus depends on the isolation of the virus from infected tissue and either histopathologic evidence of local replication or clinical symptoms consistent with infection. Confirmation of infection can be confused by latent infection in some tissues, such as the tonsils, and intermittent and sometimes prolonged shedding of virus from throat or in the stool for months to years after primary infection. 25, 26 Direct detection of adenovirus from clinical isolates is generally achieved by culture, direct fluorescent antigen detection, or polymerase chain reaction (PCR). 2, 27 Adenovirus can readily be grown in HEK and A549 cell lines (see Figure 173 -1), with typical cytopathic effect or fluorescent antibodies used to confirm infection. Molecular
KEY CONCEPTS
• Novel strains of adenovirus 11 and 14 have recently been identified as a cause of clinically significant, sometimes severe infection, in otherwise healthy adults and children.
• The novel coronavirus, MERS-CoV, has emerged to cause severe respiratory infections in the Arabian Peninsula.
• A short inhibitory RNA has shown promise in the management of respiratory syncytial virus (RSV) in lung transplant recipients but is not yet approved for the treatment of RSV.
• Human rhinoviruses are the most common cause of the common cold and are also common triggers of exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
• Human metapneumovirus is a significant cause of disease in young children
• Human bocavirus 1 is a newly discovered respiratory pathogen although coinfection with other viruses is often documented.
techniques are used increasingly for the diagnosis of adenovirus and generally have the highest yield of the various diagnostic methods. 27, 28 Unfortunately many respiratory virus multiplex panels have low yields for adenovirus in patients with clinical infection; this is especially true if respiratory samples are collected and the respiratory tract is not the primary site of infection. 29 Quantitative PCR assays can be used to predict progression to disseminated disease in pediatric and, to a lesser extent, adult stem cell transplant (HSCT) recipients and to assess response to antiviral therapy. 28, [30] [31] [32] [33] Clinical Manifestations
Adenovirus infections are associated with a wide range of clinical manifestations, including respiratory tract, ocular, gastrointestinal tract, genitourinary tract, and central nervous system (CNS) infections, among others. Disseminated infection can also occur, typically in the immunosuppressed host.
RESPIRATORY TRACT INFECTIONS
Pharyngitis, laryngotracheitis, bronchitis and pneumonia have all been described. Typically, symptoms that include nasal congestion, coryza and cough are often accompanied by systemic manifestations, such as generalized malaise, fever, chills, myalgia and headache; abdominal pain, an exudative tonsillitis and cervical adenopathy are often frequently observed. 34, 35 If conjunctivitis accompanies the above signs and symptoms, the disease is designated as pharyngoconjunctival fever. 7, 36 Rarely a pertussis-like syndrome has been described, typically caused by AdV 5. 37, 38 Pneumonia, usually with diffuse bilateral interstitial infiltrates, has been described and may be particularly severe with AdV 3, 7, 14 and 21. 5, [39] [40] [41] [42] [43] [44] The recent outbreak of severe AdV 14 resulted in significant morbidity and mortality in some patients. 5, 44 Most individuals presented with fever and cough and most required hospitalization (76%), supplemental oxygen (61%), and critical care (47%), while a minority received vasopressors (24%) or died (18%). 5 Older age, chronic underlying condition, low absolute lymphocyte counts and elevated creatinine levels were associated with severe illness.
OCULAR INFECTIONS
The two most common manifestations of ocular adenovirus infection are pharyngoconjunctival fever and epidemic keratoconjunctivitis (EKC). Pharyngoconjunctival fever is typically a milder form of acute follicular conjunctivitis that accompanies febrile pharyngitis or cervical adenitis. 7, 36 Symptoms typically resolve without sequelae and no treatment is indicated. Epidemic keratoconjunctivitis (EKC) is a more serious disease with a much longer time to recovery. Following an 8-10 day incubation, a follicular conjunctivitis with edema of the eyelids, pain, lacrimation, photophobia, preauricular lymph node hypertrophy and, rarely, self-limited painful corneal opacities develop. 45, 46 Epidemic keratoconjunctivitis, typically caused by adenovirus types 8, 19, and 37, was first seen in shipyard workers whose eyes had been slightly injured by chips of rust or paint. Although patients may experience significant pain and blurry vision, EKC typically resolves without permanent corneal damage over 4 weeks. 47, 48 
GASTROINTESTINAL TRACT INFECTIONS
Up to 10% of pediatric cases of diarrhea are caused by the group F AdV 40 and 41. Higher rates of adenovirus-induced diarrhea have been described with seasonal outbreaks in low-and middle-income areas of the world. 2 Adenovirus-associated diarrhea is typically prolonged, lasting 8-12 days. Outbreaks in closed communities and clinical settings have been described. 49 Mesenteric adenitis is common and clinically mimics appendicitis or results in intussusception in young children. 16, 50 Adenovirus infection may masquerade as rejection in small bowel transplant recipients and should be ruled out on all biopsies from such patients. 4, 51 
GENITOURINARY TRACT INFECTIONS
Hemorrhagic cystitis typically presents as microscopic or macroscopic hematuria and pain and cramping of the bladder, and is associated with AdV 11 and 21. 52 Adenovirus tubulointerstitial nephritis occurs mostly commonly in kidney transplant recipients and presents as transient elevation of serum creatinine and hemorrhagic cystitis. [53] [54] [55] 
OTHER MANIFESTATIONS OF ADENOVIRUS
Other rare manifestations include meningitis, encephalitis, myocarditis and dilated myocardiopathy. [56] [57] [58] Additionally, echogenic liver lesions with or without hydrops and neural defects in fetuses have also been described. 59 
ADENOVIRUS DISEASES IN IMMUNOCOMPROMISED PATIENTS
Adenovirus disease in immunocompromised adults and children ranges from asymptomatic shedding to progressive, often fatal disseminated disease. 28, [60] [61] [62] [63] Risk factors for adenoviral infection in the HSCT population includes allogeneic donor (8.5-30% vs 2-12% for autologous donor), pediatric age groups (20-47% vs 9-13.6% for adults), T cell-depleted grafts (45% vs 11%), use of alemtuzumab, cord blood donor and patients with acute graft-versus-host disease Kong, Vietnam, Singapore, Taiwan and Canada in a matter of weeks; at the end of the 6-month epidemic, more than 30 countries were affected, resulting in 8096 confirmed infections, and 774 deaths (9.6%). 87 The primary mode of transmission was via respiratory droplets; the basic reproductive number (R0) of SARS was in the range of 2.2-3.7. 79, 82, 87 However, frequent nosocomial outbreaks and 'superspreading events' had greatly exacerbated its transmission. 88 Notably, 21% of SARS victims were healthcare workers; and the disease attack rate in hospitals was between 10% and 60%. 78, 82 Viral kinetics (peak at the time of clinical deterioration), application of aerosol-generating procedures and devices (e.g. intubation, resuscitation, oxygen or nebulizer therapy, bilevel positive airway pressure (BiPAP)), overcrowdedness and lack of proper isolation facilities in hospitals are some of the explanations. [88] [89] [90] A community 'super-spreading event' that occurred in a private housing estate in Hong Kong involved over 300 residents. Drying up of a 'U-shaped' bathroom floor drain and backflow of contaminated sewage (from a SARS patient with diarrhea), coupled with the toilet's exhaust fan, might have created infectious aerosols that rose with warm air along the building's air-shaft; these were then dispersed by wind flow, causing long-range transmission to nearby buildings. 90 This and other evidence suggested that SARS could be 'opportunistically' airborne. 78, 89 The first cases of MERS-CoV infections emerged in June 2012 in Saudi Arabia and Qatar. As of May 2015, a total of 1180 confirmed infections and 483 (41%) deaths had been reported. 78, 91 The Middle Eastern countries of Saudi Arabia, Qatar, Jordan and United Arab Emirates were predominantly affected, but imported cases to UK, Netherlands, USA and Asia were reported. 91, 291 The largest outbreak outside the Middle East occurred in South Korea in 2015, which involved multiple hospitals and 185 individuals, causing 36 (19.5%) deaths. Although zoonotic transmission is implicated, the majority of infected cases did not report a history of direct animal contact. Epidemiological investigations suggested sporadic transmission of disease with multiple introductions into the at-risk population. It was found that occupational exposure to camels (e.g. shepherds, slaughter-house works) was associated with 15-23 times higher risk of seroconversion (2.3-3.6%) than the general population (<0.2%). Also, a large number of younger (15-44 years) infected individuals, who develop no or mild symptoms might exist and serve as the source of infection for those without direct animal contact. 78, 91, 92, 292 Secondary transmission in household is not uncommon, which occur in over 20% of case clusters. Transmission is typically highly efficient in the hospital settings via infectious droplets/aerosols, leading to frequent occurrence of nosocomial outbreaks, as in the case of SARS. 78, [93] [94] [95] [96] 293, 294 Pathogenicity The cellular receptor for HCoV-229E is aminopeptidase N (APN) or CD13; the cellular receptor for HCoV-OC43 is 9-O-acetylated sialic acid on the cell surface. Like SARS-CoV, HCoV-NL63 binds to the ACE2. 85 Humans have no pre-existing immunity to SARS-CoV or MERS-CoV. These novel viruses have the ability to evade innate host defenses (e.g. type I interferon responses and related mechanisms), and replicate efficiently in host tissues (respiratory and intestinal tract cells; kidney cells also for MERS-CoV). 78, 80, 82, 83 In addition to lytic cell damage, uncontrolled replication of SARS-CoV leads to unabated inflammatory cytokine activation (commonly known as 'cytokine storms'), which is implicated in the development of progressive pneumonitis, diffuse alveolar damage and acute respiratory distress syndrome (ARDS), and hemophagocytic syndrome. 79, 97 High viral load and slow viral clearance due to inefficient host responses are associated with progressive disease and fatal outcomes. 82, 98, 99 Pathogenesis data for MERS-CoV are limited; a macaque model has shown active viral replication in lung tissues causing localized-to-widespread lesions and clinical illness, which only abates after 1 week of illness. Infected marmosets can develop severe interstitial pneumonia similar to humans cases. Neutrophil and macrophage infiltration and alveolar oedema are noted. 78, 100, 101 (GVHD). 4, 28, [63] [64] [65] Although disseminated disease only effects 1-7% of HSCT recipients it is associated with a significant risk of mortality (8-26%). 4, 28, 63, 66 Incidence among solid organ transplant recipient populations is highest in small bowel and liver transplant recipients, pediatric transplant recipients, patients who receive antilymphocyte antibodies, and patients with donor-positive/recipient-negative adenovirus status. 60 Asymptomatic adenovirus DNAemia is common among solid organ transplant recipients and generally is not associated with progression to symptomatic disease. 67, 68 Management Although no antivirals are specifically approved for the treatment of adenovirus, several have in vitro and in vivo experimental data to support their use. 4 63,69-73 While no single agent has consistently been effective in all cases, existing data suggest that cidofovir and its lipid ester analogs (CMX001 or brincidofovir) are most effective in managing adenovirus infections. 4, 63, 74 Adenovirus-and multi-virus-specific T cells are an emerging potential therapy that can safely be used with a low frequency of de novo graft-versus-host disease and a complete or partial response in the adenovirus infection. 75, 76 Serial measurement of quantitative viral load is predictive of response to any therapeutic intervention.
Coronavirus
Nature
Coronaviruses are large, lipid-enveloped, positive-sense, singlestranded RNA viruses. Human coronaviruses (e.g. hCoV 229E, OC43, NL63) commonly cause mild upper respiratory tract infections, although occasionally result in more severe disease in immunocompromised individuals. 77 However, two novel human coronaviruses, the severe acute respiratory syndrome-associated coronavirus (SARS-CoV), and a recently identified Middle East respiratory syndromeassociated coronavirus (MERS-CoV) may cause serious viral pneumonitis, leading to hospitalizations and deaths. 78, 79, 289 Viral genome analyses revealed that SARS-CoV belongs to Group B and MERS-CoV belongs to Group C betacoronavirus, respectively, and both are closely related to coronavirus strains found in bats. [78] [79] [80] Intermediate mammalian hosts, such as civet cats, have been implicated for SARS-CoV before its adaptation for human transmission, and emerging evidence (through virus or antibody detection) suggest that the dromedary camels are likely the host for MERS-CoV. 78, 79, 81, 290 The surface spike glycoprotein (S-protein) of coronaviruses is a key virulence factor which attaches the virus to host cells, determining its host range and tissue tropism, and it is a target of the neutralizing antibodies. SARS-CoV uses human angiotensin-converting enzyme 2 (ACE-II) as the primary cellular receptor; the human cellular C-type lectin (DC/L-SIGN) may be the alternative. 82 MERS-CoV has been shown to bind to dipeptidyl peptidase 4, (DPP4; also called CD26), an interspecies-conserved protein found on the surface of several cell types, including the nonciliated cells in human airways, which can explain its broadened host range and its ability to cause cross-species, zoonotic transmission. 83 
Epidemiology
HCoVs are ubiquitous among humans and are the major cause of respiratory disease, accounting for up to 30% of all common colds. Serologic studies have also suggested that one-half of the infections with coronaviruses are asymptomatic. 84 Two more newly-described coronaviruses, HKU1 and NL63, are also common causes of typically mild, self-limited colds. 85 More severe clinical disease has been described in young children, the elderly and in immunocompromised patients. 86 SARS-CoV emerged in Southern China (Guangdong province) in late 2002; the first victims were those involved in live animal trade and food handlers at restaurants which serve exotic animal meat. 79 Through international air travel, the disease quickly spread to Hong but their efficacies are questionable. 78, 102, 111 Ribavirin, though shown to be active in vitro, did not seem to provide any clinical benefit. An HIV protease-inhibitor (lopinavir-ritonavir) with in vitro activity against SARS-CoV was reported to cause viral load reduction and fewer ARDS and deaths in 41 patients; however, the study was uncontrolled. 112 Another study reported that 19 patients who received 'convalescentplasma' from recovering individuals, which contained neutralizing antibodies, had better clinical outcomes (survival 100% vs 66%, discharge rates 78% vs 23%). 113 Subsequent in vitro and animal (ferrets, hamsters, macaques) studies have shown that monoclonal antibodies targeting the S-protein may provide neutralizing activity against SARS-CoV, resulting in viral load reduction and resolution of lung lesions. 114, 115 In vitro and animal (mice, macaques) studies show that type I interferons, if given prophylactically or shortly after exposure, may protect against SARS. 116 In a small clinical study (n=9), interferonalpha given within 5 days was associated with lower rates of intubation (11% vs 23%) and death (0% vs 8%). 117 Against MERS-CoV, available data have shown that type I and type III interferons are active in vitro; a combination of IFN-α 2b and ribavirin given hours after infection appears to reduce lung injury in a macaque model. 118 Clinical data are limited; among the few patients who received such treatment, no consistent result was observed. In one retrospective study, survival was 30% versus 17% at 28 days, but it did not reach statistical significance. 80, 92, 95, 104, [108] [109] [110] 295 Animal models have suggested potential benefits of other antiviral agents or antibody-based therapies, but no clinical data have been published to date. 119, 296, 297 Systemic corticosteroid treatment is highly controversial. While favorable clinical and radiological responses have been reported, controlled data are lacking. 102, 106, 111 In the only randomized, placebocontrolled study performed during the SARS outbreak, early corticosteroid treatment within the first few days delayed viral clearance. 98 A later systematic review has ded that corticosteroid is not associated with definite benefit, but is likely to be harmful (e.g. metabolic side effects, bacterial and fungal superinfections, avascular osteonecrosis, acute psychosis). 111 Currently, corticosteroid therapy is not recommended in SARS-CoV, MERS-CoV and avian influenza infections, perhaps except in cases with refractory septic shock and adrenal insufficiency, and should only be given at a low dose (e.g. hydrocortisone 50 mg Q8H). 78, 91 Respiratory Syncytial Virus
Nature and Pathogenicity
Respiratory syncytial virus (RSV) is an enveloped, single-stranded RNA paramyxovirus that includes two major groups, A and B, each of which consists of 5 to 6 genotypes. The RSV genome encodes two nonstructural (NS1 and NS2) and nine structural proteins, including the F (fusion) and G (attachment) glycoproteins on the viral envelope. Antibodies against the F and G proteins are neutralizing, and have been shown to confer protection against RSV infection in animal models. Immunity after primary infection (which generally occurs by 2 years of age) is partial and short-lived; thus, reinfections can occur throughout life. 120 Low serum neutralizing antibody levels in adults predicts infection risk and disease severity. 121 Immunologic mechanisms (e.g. cytokine responses) have been implicated in the pathogenesis of severe RSV diseases; however, emerging evidence suggests that uncontrolled viral replication, as indicated by high respiratory tract viral load, drives disease manifestations and is associated with severe clinical outcomes. 120, [122] [123] [124] [125] Such findings provide an important rationale for the approach to antiviral drug development against RSV. 122 Epidemiology RSV is known to be an important cause of lower respiratory tract infection in infants and young children (e.g. acute bronchiolitis, wheezy attacks), resulting in hospitalizations and deaths. 126 In adults, it has been estimated that RSV infects 3-10% of the population Prevention There is no vaccine or chemoprophylaxis available for coronaviruses at present. 102 Droplet and contact precautions, including the use of face masks, are advisable to prevent transmission. As transmission could be opportunistically airborne, appropriate isolation precautions (in negative-pressure facilities if available) should be implemented in all hospitalized patients confirmed with novel coronavirus infections, particularly when respiratory procedures and devices are applied. [88] [89] [90] [91] 
Diagnostic Microbiology
A high index of suspicion, together with detailed clinical and epidemiological assessments (e.g. travel history to affected areas, case clustering), is required for the diagnosis of novel coronavirus infections. 88, 103 RT-PCR is the diagnostic test of choice. A combination of upper respiratory (nasal, pharyngeal, nasopharyngeal), lower respiratory (higher yield due to higher viral levels, e.g. sputum, tracheal aspirate, bronchoalveolar lavage (BAL) whenever available), blood and fecal samples, and repeated sampling should be considered to maximize the chance of virus detection. [103] [104] [105] A single negative test from an upper respiratory sample may be insufficient to rule out the diagnosis. For SARS-CoV, plasma RT-PCR can detect viremia as early as day 2-3 after symptom onset, and its level may have prognostic value. 88, 99 Virus culture (e.g. using Vero cells) is confirmatory, but the delay to a result prevents its use for clinical management; also biosafety level-3 facilities are required. Serological diagnosis is retrospective and largely used for epidemiological surveillance purposes. 103 Clinicians should refer to their local reference laboratories for coronavirus testing (e.g. pancoronavirus RT-PCR, specific SARS-CoV and MERS-CoV RT-PCR). 87, 91 
Clinical Manifestations
The incubation period of SARS is about 4-6 days (range 2-16 days). Patients initially develop fever, chills and rigor, which partially subside in a few days. These are then followed by resurgence of high fever, cough, shortness of breath and the development of pneumonia. 78, 88 Chest radiographs first reveal patches of consolidation and groundglass changes, which rapidly progress in the next few days to involve multiple lobes. CT scan of thorax may show features resembling bronchiolitis obliterans or organizing pneumonia, such as peripheral airspace consolidation. 78, 79, 88 Laboratory features include lymphopenia, thrombocytopenia, elevated transaminases, creatinine kinase and lactate dehydrogenase. 88 Around day 10-14, 15-25% of patients further deteriorate and develop refractory respiratory failure and ARDS. 106 About 20% of patients develop profuse diarrhea which contains highly infectious virus particles; renal failure is rare. 107 Other complications include ventilator-associated pneumonia (e.g. MRSA), pneumothorax and pneumomediastinum. 106 The overall death rate of SARS was 6-16%. The age-stratified case fatality rate was: <25 years: <1%; 25-44 years: 6%; 45-64 years: 15%; and >65 years: >50%. 78, 87, 106 Young children (e.g. <5 years) typically have mild disease; fatality is rare.
Available data indicate that the clinical features of MERS-CoV are similar to those of SARS. Patients develop high fever and chills, cough, shortness of breath and progressive pneumonia in about 1 week after symptom onset. Imaging findings include multiple, patchy consolidations and ground-glass changes. In addition to lymphopenia, thrombocytopenia and elevated liver enzymes, acute renal failure seems to be a common feature. 80, 92, 95, 104, 108 The majority of adult patients with severe infection are older (mean age 60 years), and had underlying conditions (e.g. diabetes mellitus, renal impairment) and required ICU care because of respiratory failure and ARDS; the associated fatality rate in such patients rate can be as high as 60-76% despite maximal medical support. 92, 108, 109 Notably, affected children usually have mild or no symptoms, as in the case of SARS. 78, 79, 110 Management At present, there is no established therapy for coronavirus infection. During the SARS outbreak in 2003, a range of agents had been used b a such as consolidation and ground-glass opacities, which are typically small, patchy and unilateral. 97, 120, 131 The majority (>70%) of adults hospitalized with RSV develop severe lower respiratory complications, including pneumonia, acute bronchitis and exacerbations of COPD/ asthma resulting in respiratory failure and hypoxemia, and 10-15% develop cardiovascular complications such as congestive heart failure or acute coronary syndrome. [127] [128] [129] 131 Bacterial superinfection occurs in at least 12-17%. 120, 127, 131 Published data suggest that around 10-18% of patients required ventilatory support because of respiratory failure and the overall mortality was approximately 8-10%; the outcomes are generally comparable to that of seasonal influenza. 128, 131 
Treatment and Prevention
At present, there is no established antiviral therapy or vaccine available for RSV. Ribavirin has in vitro activity against RSV and in animal models, palivizumab (an RSV-specific monoclonal antibody directed against the F glycoprotein) has been shown to reduce viral titers and replication in pulmonary tissues. 120, 133 In randomized clinical trials, palivizumab given prophylactically to very young high-risk children was shown to reduce hospitalizations related to RSV infections. 134 In immunocompromised adults, ribavirin (aerosolized or systemic administration) and palivizumab have been used to treat RSV infection with the aim of reducing progression to lower respiratory disease and death, with variable results. 120, 132, 133, 135 There is lack of controlled data, and it is not known whether these approaches can be applied to older, non-immunocompromised adults. New antiviral agents (e.g. fusion protein and polymerase inhibitors, siRNA) and newer generation antibody therapies are under active research. 120, 136, 137, 298 Systemic corticosteroids are commonly used to treat wheezing and exacerbations of COPD/asthma in adults, including those triggered by viral infections. Randomized controlled trials of corticosteroid therapy in young children with RSV infections have revealed a lack of clinical benefit and inconsistent control of inflammatory cytokine responses. 138, 139 A recent study of corticosteroids in adults reported that virus control seemed to be unaffected but humoral immunity against RSV was diminished. 140 It is suggested that the decision to treat RSV patients with corticosteroids should be weighed against the potential risks (e.g. bacterial superinfections) and be limited to a short course if used. 131, 140 Because of the high rates of secondary infections, it is prudent to test and treat bacterial pathogens according to local resistance profiles. In addition to Streptococcus pneumoniae and Haemophilus influenzae, Pseudomonas aeruginosa and other gram-negative bacilli annually. Although most infections are mild, severe lower respiratory tract infections can occur, especially among older adults (e.g. >65 years) and those with underlying conditions (e.g. chronic lung diseases, chronic cardiovascular diseases). 120, 127 RSV has been shown to account for 5-15% of community-acquired pneumonia, 9-10% of hospital admissions for acute cardiorespiratory diseases and excessive deaths among adults during seasonal peaks. 120, 128, 129 Outbreaks among nursing home residents are common, but under-recognized. The disease burden of RSV has been shown to approach that of seasonal influenza. [129] [130] [131] Patients who are profoundly immunosuppressed, such as hematopoietic stem cell transplant (HSCT) recipients, are at particularly high risk for severe RSV infection (2-17%), which can be rapidly fatal. 132 
Diagnostic Microbiology
RSV infection is clinically indistinguishable from other viral respiratory infections and diagnosis requires laboratory testing. Upper respiratory tract specimens (e.g. nasal, throat, nasopharyngeal) are commonly used, but lower respiratory samples (e.g. tracheal aspirate, BAL) should be considered whenever available. The gold standard for diagnosis is by RT-PCR; other tests such as antigen assays (e.g. enzyme immunoassays) and culture have much lower sensitivities (see Figure  173 -2), especially among adults because of their lower viral loads. 120, 131 A negative antigen assay result cannot be used to rule out RSV infection. Serology to detect RSV-specific IgG antibodies may also assist with the diagnosis and, if available, can be used in combination with RT-PCR to maximize the yield. 120 
Clinical Manifestations
RSV infections in infants and young children can lead to severe lower respiratory tract illnesses such as pneumonia and bronchiolitis. 126 The clinical manifestations of RSV infection in adults are diverse and often determined by the underlying conditions (e.g. chronic lung diseases) and degree of immunosuppression. In healthy young adults, RSV may cause self-limiting upper respiratory illnesses; in the profoundly immunosuppressed, progressive pneumonitis can occur (17-84%), resulting in high mortality (7-83%). 120, 132 Older adults hospitalized for RSV infection may present with fever, cough, sputum production, wheezing and dyspnea. Although wheezing and dyspnea may be more common with RSV, and the magnitude of fever sometimes lower, such findings could not reliably differentiate it from influenza. 120, 131 Radiographically, about 50-60% of cases show active pneumonic changes blood vessels, transudation of plasma and increased glandular secretions. 151 Together, these result in local congestion and trigger sneeze and cough reflexes. Immunity, which is type-specific and short-lived, results in eventual clearance of virus locally.
While the majority of replication was initially felt to be limited to the upper airway, a growing body of evidence suggests that HRVs can and frequently may replicate in the lower airways. This is likely to be more common among individuals with lower airway signs and symptoms and may contribute to pneumonia, which may occur rarely in immunocompromised adults and children. Further, this lower airway involvement may contribute to asthma and COPD exacerbations. 141, 152 Prevention There are currently no available vaccines against HRV. The cornerstone against transmission is diligent hand hygiene. Symptomatic adults should be advised to wash hands frequently and use disposable tissues. Currently, droplet precautions are recommended to prevent nosocomial transmissions of rhinoviral infections.
Diagnostic Microbiology
While HRV can be grown in cell culture, molecular diagnostics are more sensitive and are currently widely available. 141, 153 Typical cytopathic effects can be seen when HRV are grown on human embryonic kidney and human fibroblast cell lines, including WI-38, human foreskin fibroblasts (HFF), MRC-5 and HeLa (see Figure 173 -3). HRV are acid labile which allows differentiation from other enteroviruses; they preferentially grow at pH 7.0 and not at 3.0. 148 Most molecular assays target the 5'UTR, a region highly conserved among all HRVs and enteroviruses; as a result, most molecular assays detect but do not differentiate between HRV and enteroviruses, although newer diagnostic platforms are circumventing this problem. 141, 153 
Clinical Manifestations
The most common manifestations of HRV infections include the common cold and exacerbations of asthma and COPD, although more serious infections, including pneumonia, have been described, particularly in immunocompromised adults and children. Following a typically 2-day incubation period, patients with colds then develop watery rhinorrhea, nasal congestion, sneezing, cough, sore throat, headaches and sometimes fever that last 7-14 days. 154 Rhinoviral colds cannot be differentiated from those caused by other pathogens. Primary viral may need to be considered in patients with underlying chronic lung diseases. 127, 131 Rhinovirus Nature Human rhinoviruses (HRVs) are members of the family Picornaviridae and the genus Enterovirus. The HRVs are positive-sense, singlestranded-RNA viruses that encode a single protein that is cleaved by the virally mediated protease. The VP1-4 proteins make up the viral capsid. 141 There are well over 100 serotypes that are generally phylogenetically organized into three different species: HRV-A (74 serotypes), HRV-B (23 serotypes) and a more recently identified HRV-C (>50 serotypes have been identified to date). 142, 143 Epidemiology HRV infections occur worldwide with peak incidence in the early fall and spring in temperate climates, although infection can occur year round. HRV-C has its peak incidence in the fall and winter in temperate regions and during the rainy season in tropical regions. 144, 145 Infections occur in all age groups. HRVs are responsible for over half of all common colds and have been increasingly associated with more severe upper and lower respiratory tract infections in children, the elderly and the immunocompromised. 141 Young children are typically responsible for introducing the virus in household settings with a secondary attack rate of about 50%. With challenge studies, most (95%) develop infection while about 75% demonstrate clinical illness. 146 
Pathogenicity
HRVs are transmitted from person to person via contact (either direct or through a fomite) or aerosol (small or large particle). 147 HRVs can survive from a few hours to as long as 4 days on nonporous surfaces and for over 2 hours on human skin. 148 The majority of HRVs bind to intercellular adhesion molecule 1 (ICAM-1) whereas a minor group of HRVs adhere to the low-density lipoprotein receptor (LDLr). 141 Heparan sulfate has also been demonstrated as an additional receptor for some HRVs. Following infection of the respiratory epithelium, significant inflammatory cytokines, including IFN-β and IFN-γ and RANTES, IP-10, IL-6, IL-8, epithelial cell-derived neutrophil-activating peptide 78 (ENA-78), bradykinins, prostaglandins and histamine, are released locally. 141, 149, 150 This, in turn, results in vasodilation of nasal of upper airway ciliated epithelial cells, 177 infection spreads to the large and small airways. 178 Peak symptoms correlate with peak viral replication. Infection of the larynx and upper trachea is associated with croup whereas bronchiolitis and pneumonia are associated with infection of the distal airways. 179 The host immune response appears to play a more important role in the pathogenesis of PIV infection than direct viral replication. 179, 180 Specifically, the key host immune responses which contribute to viral clearance, including the innate immune responses, CD8+ and CD4+ T-cell responses, interferon production and local and system IgA, IgE and IgG responses, are also the key drivers of the clinical signs and symptoms of infection. 179 While both humoral and cellular immune responses are critical for clearance of infection, defects in cytotoxic T-cell response are associated with progressive disease, as is demonstrated by the increased risk of progressive and fatal disease in HSCT recipients. 174 
Prevention
There is currently no licensed vaccine against PIV, although several candidates that appear to produce neutralizing antibodies to the HN and F proteins are being investigated. 163 Most of the contemporary vaccine candidates have focused on reverse genetic technology applied to live, attenuated intranasal vaccines. 159 Further, some of the candidate vaccines afford protection against both PIV and RSV. 181 Nosocomial outbreaks of PIV infection have been documented, highlighting the importance of standard and contact precautions and use of private rooms whenever possible. 24 Respiratory precautions are not necessary, because the droplets are large and do not aerosolize.
Diagnostic Microbiology
PIV can be diagnosed by culture, antigen detection, or nucleic acid testing. PIV is stable in viral transport medium at 4°C for up to 5 days. Freezing to −20°C does decrease infectivity of the virus, but long-term storage can be achieved easily by adding sucrose or glycerol to the holding media and freezing to less than −70°C. 162 LLC-MK2 rhesus monkey kidney, Vero African green monkey kidney, and NCI-H292 human lung carcinoma cell lines using standard and shell vial techniques can be used to culture PIV; 163 fixed-mixed cell lines, such as R-Mix (Diagnostic Hybrids, Athens, OH), have a sensitivity that approaches that of standard cell culture lines for the detection of PIV. 162, [182] [183] [184] Trypsin is required for the growth of PIV-1 and PIV-4 but not PIV-2 and PIV-3. 163 Hemadsorption-inhibition, hemagglutination inhibition or immunofluorescence is used to identify the PIV in cultures (see . 162 There are currently no approved rapid antigen kits available for the detection of PIV although monoclonal antibodies can be used to detect the PIV serotypes in primary patient samples and from cell cultures. 162, 185 Polymerase chain reaction (PCR)-based tests, typically directed toward the hemagglutinin-neuraminidase (HN) gene, are now considered the gold standard for the diagnosis of PIV. Such assays typically have higher yield over cultures for the diagnosis of PIV. [186] [187] [188] [189] Despite the advantages of highly multiplexed PCR-based systems in detecting a wide range of viruses, the diagnostic yield for PIV is not consistent for all available systems. [190] [191] [192] 
Clinical Manifestations
Parainfluenza viruses cause a variety of upper and lower respiratory tract illnesses, ranging from mild cold-like syndromes to lifethreatening pneumonias.
PEDIATRIC DISEASE
Most infections in children are limited to the upper respiratory tract with only about 15% involving the lower respiratory tract. 193 Upper tract disease may involve the entire airway, including the middle ear and sinuses. [193] [194] [195] PIV-1 and -2 are associated with croup or laryngotracheobronchitis in children, which is characterized by fever, rhinorrhea and pharyngitis and is typically followed by a barking cough. 161, 196 otitis or rhinosinusitis may also occur with HRV and typically occurs earlier than bacterial superinfections that occur later in the course of colds. Lower airway infections, including croup, bronchiolitis and pneumonia have been described. 148, 155, 156 HRV are common triggers for exacerbation of asthma and COPD and may be caused by the direct infection of the lower airway or the stimulation of inflammatory, immunological, or neurogenic mechanisms. 157 Management While a number of small molecule antivirals (capsid-binding agents: pleconaril, vapendavir and pirodavir; 3C protease inhibitors: rupintrivir; soluble ICAM-1: tremacamra) and complementary medical interventions (echinacea, zinc) have been studied for the treatment of rhinoviral colds, none has been approved for use. Interferons have been shown to prevent HRV colds, but they have not been documented to have positive therapeutic effects. As a result, the mainstay of treatment of rhinoviral colds remains symptomatic treatment with analgesic agents, decongestants, antihistamines and antitussives. 141 
Parainfluenza Virus
Nature Parainfluenza viruses (PIVs) are single-stranded, enveloped RNA viruses belonging to the genus Paramyxovirus in the Paramyxoviridae family. 158, 159 The single strand of negative-sense RNA encodes at least six viral proteins: the nucleocapsid protein (NP), the phosphoprotein (P), the matrix protein (M), the fusion glycoprotein (F), the hemagglutinin-neuraminidase glycoprotein (HN), and the RNA polymerase (L). 160 There are four major serotypes of human PIV (PIV-1, 2, 3, 4) that are defined by complement fixation and hemagglutinating antigens. [161] [162] [163] PIV-1 and 3 are members of the genus Respirovirus, whereas PIV-2 and 4 are members of the genus Rubulavirus.
Epidemiology
Initial infection with parainfluenza typically occurs early in childhood, most commonly in children less than 5 years old. Serologic studies have demonstrated that PIV-3 affects up to 50% of children within the first year of life with PIV-1 and 2 causing initial infections later, generally between 3 and 5 years old. 164, 165 Most adults have antibodies to PIV. PIV is responsible for 20-40% of lower respiratory tract infections and is the second most common viral cause of hospitalization in children. 166 With contemporary molecular diagnostics, PIV has also been demonstrated to be the second or third most commonly isolated virus in hospitalized adults, aged 16-64 years old. [167] [168] [169] In both adults and children, re-infection is common despite the presence of antibodies formed during prior infection. 170 In tropical and subtropical regions, parainfluenza viruses do not show seasonal variations, while in temperate regions, such as the USA, PIV-1 and PIV-2 cause seasonal outbreaks in the fall (September-December) and PIV-3 causes epidemics during the spring (April-June). 171, 172 In years when there is no PIV-1 circulating (typically even-numbered years), PIV-3 activity is generally greater. 172 PIV-4, which generally causes a milder degree of illness, is more common in the autumn and winter months. 173 Parainfluenza is one of the more common causes of respiratory viral infections in patients with hematologic malignancies, hematopoietic stem cell transplantation, or solid organ transplantation and is associated with a high rate of progressive disease involving the lower airway and an increased mortality rate. 174, 175 Pathogenicity Parainfluenza viruses are transmitted by direct person-to-person contact through large respiratory droplets and contact with fomites contaminated with respiratory secretions. 176 Clinical symptoms typically develop after a 2-6 day incubation period. After initial infection PIV-3 is associated with more distal lung involvement, particularly in the first 6 months of life. 161, 197 PIV-4 is generally associated with mild upper respiratory infections or asymptomatic infection, although more severe disease has been described in children with underlying cardiopulmonary disease or immune compromise. 161, 198 Nonrespiratory complications of PIV include meningitis, myocarditis, pericarditis, and Guillain-Barré Syndrome. [199] [200] [201] [202] ADULT DISEASE PIV is responsible for 1-15% of acute, typically mild respiratory illnesses in adults with higher rates and more significant morbidity in older adults. 203, 204 Higher rates of pneumonia (11-14%) have been described in the elderly. 205, 206 Wider use of more sensitive molecular assays have demonstrated that PIV is a significant cause of communityacquired pneumonia and exacerbations of asthma and chronic bronchitis. [207] [208] [209] [210] [211] [212] [213] 
PARAINFLUENZA VIRUS IN IMMUNOCOMPROMISED PATIENTS
Parainfluenza virus causes significant direct and indirect morbidity and mortality among immunocompromised adults and children. 174 PIV can cause asymptomatic shedding, particularly among HSCT been described more frequently among immunocompromised patients and the elderly. 248, 251, 253 Most children are infected by 5 years of age. 254 hMPV is the second most frequently isolated viral pathogen, after RSV, in children presenting with bronchiolitis. 248 Infections typically occur in the late winter and spring in temperate climates and in the spring and summer in subtropical regions. 254, 255 Epidemic peaks typically occur 1-2 months later than RSV epidemics annually. 248 Pathogenicity hMPV is likely to be transmitted by direct or close contact with contaminated secretions; large particle aerosols, droplets and fomites may also result in transmission. There is typically a 5-day interval between onset of symptoms in an index case and the onset of symptoms in household exposed contacts. 256 hMPV G protein binds to the integrin α-V-β-1 receptors on respiratory epithelial cells. 248, 257 Local replication in the airway is associated with upper respiratory tract signs and significant airway inflammation. 258 Viral replication also induces mucus hyperproduction and hyperplasia of the respiratory epithelium which may result in airway obstruction and hyperresponsiveness to methacholine challenge. 259 Replication results in an increase in IL-8, IL-12, tumor necrosis factor, IL-6, and IL-1β, although levels are lower than those observed with RSV infection. 260 
Prevention
There is currently no licensed vaccine against hMPV, although several are currently under investigation. Most of the candidate vaccines utilize chimeric viruses, live-attenuated viruses and subunits of the virus. 248 Nosocomial outbreaks have been described which highlight the importance of droplet and contact precautions to prevent transmission.
Diagnostic Microbiology
Although hMPV may be grown in tertiary monkey kidney cells, Vero cells, LLC-MK2-cells, BEAS-2B cells, A549 cells and HepG2 cells, yields are often low and require prolonged incubation. 248 Cytopathic effects typically can be observed after 10-21 days and range from syncytia formation to rounding of the cells. 254 Direct immunofluorescence assays (DFA) with virus-specific antibodies are available and allow detection of virus in direct patient specimens and cell culture. DFA is less sensitive than PCR but is often more widely available. 248 Molecular diagnostics, as either a singleplex or multiplex assay, are commercially available and have the highest yield in detecting hMPV. Most PCR assays detect all hMPV genotypes and rely on conserved and essential regions within the N, F or L gene. 248, 261 The sensitivity varies by assay and is lower for most multiplex assays as compared to singleplex assays. Serologic diagnosis can be made by ELISA methods but is not widely available. 248 
Clinical Manifestations
hMPV is associated with respiratory tract infections in all age groups. Among children, the most common symptoms are rhinorrhea, cough or fever, although conjunctivitis, vomiting, diarrhea and rash have been reported infrequently. 262 Encephalitis is a rare manifestation of hMPV infection. 263, 264 Although hMPV and RSV are generally indistinguishable, fever is more frequent in children with hMPV, while rhinorrhea is more commonly observed in RSV-infected individuals. 248, 265 Children appear to be at higher risk of developing bronchiolitis, pneumonia, croup and possibly asthma exacerbation, particularly when younger than 2 years of age. Most hospitalizations are the result of bronchiolitis and pneumonia in children. Coinfection with hMPV and RSV results in more severe disease and an increased risk for admission to the ICU and a 10-fold increase in the need for mechanical ventilation. 266 The typical duration of symptoms is around a week with viral shedding typically for 1-2 weeks. 254, 255 Repeat infection has clearly been documented although subsequent infections are typically limited to recipients, which may contribute to nosocomial spread. 214 Progression to the lower respiratory tract complicates 13-43% of cases and is associated with enhanced mortality. 175, [214] [215] [216] [217] [218] [219] Rarely, lower airway involvement will be characterized by small peribronchial nodules on CT radiography. 220 Steroids, in a dose dependent manner, are associated with increased risk of progression from upper to lower tract disease and mortality. 217, 221, 222 Other risk factors for progressive disease include onset early post-transplant, allogeneic (matched unrelated and matched related) donor, presence of lymphocytopenia, active graftversus-host disease and pediatric age group. 174, 175, 221, 223 Reduced intensity conditioning appears to be a risk factor for late onset (≥ 30 days) PIV infection. 223 PIV infection is associated with a 17.9 greater odds of developing severe airflow declines following infection. 224 Parainfluenza has also been demonstrated to cause severe disease in patients undergoing chemotherapy, with enhanced risk of progression to severe lower respiratory infection in patients with severe lymphocytopenia. 225, 226 Parainfluenza virus infections among lung transplant recipients have been associated with significant short-and long-term pulmonary dysfunction. 71, 227 In addition to local acute, direct virologic effects on the lung of transplant recipients, PIV, particularly with lower tract infection, is associated with development or progression of bronchiolitis obliterans or bronchiolitis obliterans syndrome (BOS). 71, [227] [228] [229] [230] 
Management
There are currently no antivirals with proven efficacy approved for the treatment of PIV infections. For children with croup, glucocorticoids and nebulized epinephrine have been associated with improved clinical outcomes. 231, 232 When approved antivirals such as ribavirin have been studied, typically in immunocompromised patients, treatment was not associated with reduction in viral shedding or mortality. 175, 202, [216] [217] [218] [219] 223, 227, [233] [234] [235] [236] [237] [238] [239] [240] One investigational agent, DAS181, which acts by cleaving the sialic acid receptors from the surface of human respiratory epithelial cells, has been shown to improve symptoms, oxygenation, pulmonary function and nasopharyngeal viral loads in treated subjects with PIV infection. [241] [242] [243] [244] Human Metapneumovirus Nature Human metapneumovirus (hMPV) is a nonsegmented negative-sense RNA virus that is a member of the Pneumovirinae subfamily of the Paramyxoviridae. There are two subgroups each with two clades of hMPV (A1, A2, B1 and B2); although all four subtypes typically co-circulate, each season often has one subtype that predominates. 245, 246 hMPV codes for similar genes to RSV except that the order is slightly different (3'-N-P-M-F-M2-SH-G-L-5') and there are no NS1 or NS2 genes. 247 Epidemiology hMPV results in typically self-limited upper and lower respiratory tract infections in all age groups with a global distribution. 248 Symptomatic disease appears to be more common among young children and the elderly. 249 Risk factors for hospitalization from hMPV infections in children include age <6 months and the presence of three or more children in the home, whereas female gender, prematurity and genotype B infection were risk factors for severe disease. 250 About 4-9% of children require hospitalization for severe respiratory symptoms or pneumonia. 248, 250 hMPV is identified in 8.5% of adults hospitalized with acute cardiorespiratory illness. 251 Risk factors for hospitalization and severe disease in the elderly include a diagnosis of COPD, asthma, cancer or lung transplantation. The average rate of hospitalization for hMPV (9.8 per 10 000 residents) is similar to the rate for influenza (11.8 per 10 000 residents) in adults ≥ 50 years old. 252 Severe, sometimes fatal infections, including pneumonia, have infection in immunocompetent individuals. In studies of wheezing children, 64% had serologic evidence of primary infection. Further, several studies that include asymptomatic control patients have documented an association between presence of HBoV and clinical symptoms. Additionally, these studies have documented a positive correlation between high copy numbers of HBoV1 DNA and HBoV1 monoinfection and respiratory symptoms. 275 Although the exact route of transmission of human bocaviruses is unknown, transmission by inhalation or contact with infectious sputum, feces or urine is probable. The mechanism of cell entry and host range are not known. Although most HBoV1 is detected in the upper airway, clinical symptoms and positive BAL specimens suggest that HBoV1 is capable of infecting the lower airways down to at least the bronchioles. 275 HBoV1 DNA is detectable in the serum suggesting dissemination beyond the airway. Likewise, HBoV1 can rarely be detected in stool with and without gastrointestinal symptoms suggesting passive spread from the respiratory to the gastrointestinal tract. 275 In vitro, HBoV1 induces IL-13, IFN-γ and IL-10 in CD4+ T cells. Children with HBoV1-associated bronchiolitis have increased levels of IFN-γ, IL-2 and IL-4 in nasopharyngeal aspirates. [280] [281] [282] 
Prevention
There is no vaccine available for HBoV. 275 Specialist advice should be sought regarding appropriate isolation practice for patients with proven HBoV infections.
Diagnostic Microbiology
Diagnosis of HBoV depends on molecular and serologic methods. While HBoV can be cultured on differentiated human airway epithelial cells, these are not widely available in the clinical microbiology laboratory. 283 PCR is not an optimal diagnostic method because of prolonged shedding and the potential for persistent infection in some tissues. Presence of HBoV1 DNA in serum may provide enhanced specificity of active infection as it correlates with HBoV1-specific IgM 61% of the time. 284, 285 Quantitative virology may also help improve the probability that HBoV detection is associated with the clinical presentation, as high viral loads (>2 × 10 8 genomes/mL) in nasopharyngeal aspirates appear to correlate with illness severity and fewer coinfections. 275, 286 Serology, particularly IgG avidity EIA, may also increase the probability that detected HBoV is truly associated with clinical disease. 275 Given the limitations of diagnostic strategies, most would recommend using two diagnostic modalities to diagnose HBoV infection.
Clinical Manifestations
Because of the limitations outlined above, there remains controversy in the causal link between HBoV1 and respiratory disease. A number of studies have correlated HBoV1 detection and the common cold, asthma, acute wheezing, bronchiolitis, pneumonia, acute otitis media and plastic bronchitis. The strongest link in the available literature is that HBoV1 may be the cause of wheezing and pneumonia. One study found a link between HBoV1 DNA in serum, cerebrospinal fluid (CSF) or stool and Kawasaki disease, 287 although this study was not confirmed by two other groups. 278, 288 
Management
No comparative studies of available antivirals have been conducted in patients with HBoV infection. Supportive measures are the only currently available therapy. 275 References available online at expertconsult.com. the upper airway. Severe, sometimes fatal infections, often involving the lower airway, have been described in adults and children with malignancy, hematopoietic stem cell and solid organ transplantation. The severity of illness is likely related to reduced cellular immune responses. Likewise, elderly adults, adults with severe cardiopulmonary disease, and residents of long-term care facilities have a higher incidence of hMPV infection with an increased risk of lower airway involvement, complications including bacterial superinfections, and death. 248 Although asymptomatic infection is common for otherwise healthy adults, such individuals may present with cold-and influenzalike illnesses. 267 Adults commonly present with cough, nasal congestion and rhinorrhea, but rarely have fever. 130 The role of hMPV in exacerbations of COPD is unclear as one large study demonstrated an association whereas another failed to identify hMPV in patients with COPD exacerbations. 268, 269 Management Generally, patients can be safely managed with supportive care, including supplemental oxygen and intravenous hydration when indicated. Bronchodilators and corticosteroids are often used empirically although there are no controlled trials of these medications for hMPV. 248 Ribavirin shows equivalent activity against hMPV (mean EC50 74µM) and RSV (mean EC50 88 µM). 270 Likewise, standard IgIV has neutralizing antibodies against hMPV (10 log 2 /0.05mL) and RSV (11 log 2 /0.05mL), whereas RSV-specific monoclonal antibodies have no activity against hMPV. 270 Neither agent has been studied prospectively for the treatment of hMPV, although there are a number of case series demonstrating clinical response in some cases. 135, [271] [272] [273] Human Bocavirus Nature Human bocaviruses were first identified through molecular screening in 2005. 274 Bocaviruses are non-enveloped, linear, single-stranded DNA viruses that are members of the Parvoviridae family. 275 There are currently four species of human bocaviruses (HBoV1-4); HBoV2 can be further divided into two strains (A and B). 276 The viral genome encodes two forms of the nonstructural protein (NS1), nuclear phosphoprotein (NP1) and two major structural proteins (VP1 and VP2). 275, 277 Epidemiology Human bocaviruses have been detected worldwide from respiratory and stool specimens. HBoV1 is predominantly a respiratory pathogen whereas HBoV2-4 have been mostly found in stool and are less clearly associated with respiratory tract infections. Although HBoV1 is most commonly detected in children 6-24 months old, it has been detected less frequently in other age groups. 275 Infection appears to occur year round with peaks of detection in the winter and spring. Although HBoV2-4 are felt to be predominantly gastrointestinal viruses, HBoV2 has been detected in nasopharyngeal specimens. 278, 279 Most children have antibodies to HBoV1 by age 6 and most adults have detectable HBoV1 antibodies. 275 
Pathogenicity
A key challenge to understanding the pathogenesis and clinical implications of HBoV is the fact that up to 83% of HBoV DNA-positive respiratory samples have evidence of coinfection with other respiratory viruses. Further, the virus is often shed for at least 6 months after initial 
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